- Home
- UBS vs BMY Comparison
UBS vs BMY Comparison
Compare UBS & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBS
- BMY
- Stock Information
- Founded
- UBS 1862
- BMY 1887
- Country
- UBS Switzerland
- BMY United States
- Employees
- UBS N/A
- BMY N/A
- Industry
- UBS Major Banks
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- UBS Finance
- BMY Health Care
- Exchange
- UBS Nasdaq
- BMY Nasdaq
- Market Cap
- UBS 118.6B
- BMY 95.0B
- IPO Year
- UBS N/A
- BMY N/A
- Fundamental
- Price
- UBS $38.14
- BMY $47.23
- Analyst Decision
- UBS Buy
- BMY Hold
- Analyst Count
- UBS 3
- BMY 11
- Target Price
- UBS N/A
- BMY $55.64
- AVG Volume (30 Days)
- UBS 1.8M
- BMY 16.4M
- Earning Date
- UBS 10-29-2025
- BMY 10-30-2025
- Dividend Yield
- UBS 1.95%
- BMY 5.27%
- EPS Growth
- UBS 84.33
- BMY N/A
- EPS
- UBS 2.21
- BMY 2.97
- Revenue
- UBS $48,193,000,000.00
- BMY $48,034,000,000.00
- Revenue This Year
- UBS $4.30
- BMY N/A
- Revenue Next Year
- UBS $3.52
- BMY N/A
- P/E Ratio
- UBS $16.76
- BMY $15.84
- Revenue Growth
- UBS 2.09
- BMY 1.26
- 52 Week Low
- UBS $25.75
- BMY $42.52
- 52 Week High
- UBS $42.57
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- UBS 43.10
- BMY 57.46
- Support Level
- UBS $37.49
- BMY $46.12
- Resistance Level
- UBS $39.84
- BMY $49.99
- Average True Range (ATR)
- UBS 0.51
- BMY 1.29
- MACD
- UBS 0.08
- BMY 0.15
- Stochastic Oscillator
- UBS 34.48
- BMY 60.49
About UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.